Capital Research Global Investors Purchases 189,436 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Capital Research Global Investors increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 44.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 615,996 shares of the company's stock after purchasing an additional 189,436 shares during the quarter. Capital Research Global Investors owned approximately 0.75% of IDEXX Laboratories worth $254,677,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. United Capital Financial Advisors LLC increased its stake in IDEXX Laboratories by 0.9% in the 4th quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock worth $1,011,000 after acquiring an additional 22 shares during the last quarter. Cranbrook Wealth Management LLC grew its holdings in shares of IDEXX Laboratories by 7.0% during the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company's stock worth $158,000 after purchasing an additional 25 shares in the last quarter. Gabelli Funds LLC increased its position in shares of IDEXX Laboratories by 5.3% in the fourth quarter. Gabelli Funds LLC now owns 500 shares of the company's stock worth $207,000 after purchasing an additional 25 shares during the last quarter. Perigon Wealth Management LLC raised its stake in IDEXX Laboratories by 1.8% in the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company's stock valued at $632,000 after purchasing an additional 26 shares in the last quarter. Finally, Summit Trail Advisors LLC lifted its position in IDEXX Laboratories by 3.3% during the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock valued at $335,000 after purchasing an additional 26 shares during the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Down 1.1 %

Shares of IDXX stock traded down $4.68 during mid-day trading on Friday, reaching $436.30. The stock had a trading volume of 413,184 shares, compared to its average volume of 629,597. The firm has a market capitalization of $35.36 billion, a PE ratio of 40.91, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50. The stock's 50-day moving average price is $420.16 and its two-hundred day moving average price is $429.68. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $548.88.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the company's stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the sale, the director now directly owns 3,061 shares in the company, valued at $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on IDXX. Piper Sandler raised their price objective on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. Barclays lifted their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. StockNews.com cut IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Saturday, April 12th. Morgan Stanley cut their target price on IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a research note on Wednesday, January 29th. Finally, Bank of America boosted their price objective on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Four equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories has a consensus rating of "Moderate Buy" and a consensus target price of $523.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.